

Martha Nowosielski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6256442/publications.pdf>

Version: 2024-02-01

29
papers

1,736
citations

567281

15
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

3388
citing authors

#	ARTICLE	IF	CITATIONS
1	MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy. <i>Cancers</i> , 2022, 14, 1579.	3.7	6
2	Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis—a safety analysis and validation of the EANO-ESMO classification. <i>Strahlentherapie Und Onkologie</i> , 2022, 198, 475-483.	2.0	7
3	ADC textural features in patients with single brain metastases improve clinical risk models. <i>Clinical and Experimental Metastasis</i> , 2022, 39, 459-466.	3.3	3
4	Perampanel in brain tumor and SMART-syndrome related epilepsy — A single institutional experience. <i>Journal of the Neurological Sciences</i> , 2021, 423, 117386.	0.6	4
5	Bilateral medial medullary syndrome following anterior screw fixation of type 2 odontoid fracture, a case report of two patients. <i>Spinal Cord Series and Cases</i> , 2021, 7, 101.	0.6	1
6	NIMG-13. RESPONSE ASSESSMENT IN GLIOBLASTOMA PATIENTS TREATED WITH DENDRITIC CELL-BASED IMMUNOTHERAPY: A COMPARATIVE ANALYSIS OF MACDONALD, RANO, MRANO, IRANO AND VOLUMETRIC MEASUREMENTS. <i>Neuro-Oncology</i> , 2021, 23, vi130-vi130.	1.2	0
7	NCMP-14. WHOLE BRAIN RADIOTHERAPY COMBINED WITH INTRATHECAL LIPOSOMAL CYTARABINE FOR LEPTOMENINGEAL METASTASIS — A SAFETY ANALYSIS AND VALIDATION OF THE EANO-ESMO CLASSIFICATION. <i>Neuro-Oncology</i> , 2021, 23, vi149-vi150.	1.2	0
8	Changes in Brain Energy and Membrane Metabolism in Glioblastoma following Chemoradiation. <i>Current Oncology</i> , 2021, 28, 5041-5053.	2.2	6
9	Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. <i>Radiology</i> , 2020, 297, 164-175.	7.3	19
10	Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. <i>Neuro-Oncology</i> , 2020, 22, 1667-1676.	1.2	9
11	Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. <i>Lancet Oncology</i> , The, 2019, 20, 728-740.	10.7	271
12	Evaluating cellularity and structural connectivity on whole brain slides using a custom-made digital pathology pipeline. <i>Journal of Neuroscience Methods</i> , 2019, 311, 215-221.	2.5	12
13	Imaging Criteria in Neuro-oncology. <i>Seminars in Neurology</i> , 2018, 38, 024-031.	1.4	17
14	Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial. <i>Cancers</i> , 2018, 10, 372.	3.7	67
15	The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space. <i>Nature Medicine</i> , 2018, 24, 1611-1624.	30.7	229
16	Diagnostic challenges in meningioma. <i>Neuro-Oncology</i> , 2017, 19, 1588-1598.	1.2	106
17	How to facilitate early diagnosis of CNS involvement in malignant lymphoma. <i>Expert Review of Hematology</i> , 2016, 9, 1081-1091.	2.2	10
18	Radiogenomics of Glioblastoma: Machine Learning–based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. <i>Radiology</i> , 2016, 281, 907-918.	7.3	236

#	ARTICLE	IF	CITATIONS
19	Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2016, 18, 1673-1679.	1.2	36
20	Nuclear Overhauser Enhancement Imaging of Glioblastoma at 7 Tesla: Region Specific Correlation with Apparent Diffusion Coefficient and Histology. <i>PLoS ONE</i> , 2015, 10, e0121220.	2.5	36
21	Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence. <i>Neuro-Oncology</i> , 2015, 17, 151-159.	1.2	90
22	Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1139-1147.	1.2	89
23	The emerging role of advanced neuroimaging techniques for brain metastases. <i>Chinese Clinical Oncology</i> , 2015, 4, 23.	1.2	13
24	Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment. <i>Anticancer Research</i> , 2015, 35, 4955-60.	1.1	7
25	An Intra-Individual Comparison of MRI, [18F]-FET and [18F]-FLT PET in Patients with High-Grade Gliomas. <i>PLoS ONE</i> , 2014, 9, e95830.	2.5	71
26	Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. <i>Neurology</i> , 2014, 82, 1684-1692.	1.1	101
27	ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. <i>Neuroradiology</i> , 2011, 53, 291-302.	2.2	90
28	¹⁸ F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma. <i>Journal of Nuclear Medicine</i> , 2011, 52, 856-864.	5.0	162
29	Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2009, 11, 22.	3.3	38